[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100420121":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":60,"collaborators":62,"id":70,"slug":11,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":11,"enrollmentInfo":79,"targetDuration":11,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Kaiser Permanente","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral niacinamide","EXPERIMENTAL",null,[13],"Drug: Niacinamide",{"label":15,"type":16,"description":11,"interventionNames":17},"Matched placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Niacinamide","Niacinamide 3 grams on the day of surgery and post-surgical days one and two",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo","Matched placebo on the day of surgery and post-surgical days one and two",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Ali Poyan Mehr, MD","CONTACT","4152644750","ali.x.poyanmehr@kp.org",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Kaiser Permanente San Francisco Medical Center","RECRUITING","San Francisco","California","94115","United States",{"type":44,"coordinates":45},"Point",[46,47],-122.41942,37.77493,{"lat":47,"lon":46},[50,51,54,56,58],{"name":31,"role":32,"phone":11,"phoneExt":11,"email":11},{"name":52,"role":53,"phone":11,"phoneExt":11,"email":11},"Ahmad Sheikh, MD","SUB_INVESTIGATOR",{"name":55,"role":53,"phone":11,"phoneExt":11,"email":11},"Andrew Avins, MD",{"name":57,"role":53,"phone":11,"phoneExt":11,"email":11},"Lance Rtherford, MD",{"name":59,"role":53,"phone":11,"phoneExt":11,"email":11},"Paul LaPunzina, MD",{"type":61,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[63,66,68],{"name":64,"class":65},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"name":67,"class":6},"Beth Israel Deaconess Medical Center",{"name":69,"class":6},"Cedars-Sinai Medical Center","100420121",false,"NCT04750616","NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial","NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury (NACAM) Trial","NACAM","Inclusion Criteria\n\n* Informed consent before any study-related activities.\n* Men or women \\>18 years of age who are scheduled for non-emergent cardiac surgery procedures requiring CPB and are at increased risk for surgery-related adverse cardiovascular outcomes.\n\nProcedures include:\n\n* CABG\n* Aortic, mitral, tricuspid, or pulmonic valve replacement or repair\n* CABG with aortic, mitral, tricuspid, and\u002For pulmonic valve replacement\n\nRisk factors for surgery related to adverse cardiovascular outcomes include one or more of the following:\n\n* Valve surgery\n* eGFR \\\u003C 45 ml\u002Fmin\u002F1.73m2\n* Documented LVEF ≤ 35% within six months before surgery\n* Documented history of heart failure\n* Insulin-requiring diabetes\n* Non-insulin-requiring diabetes and the presence of ≥+2 proteinuria on urinalysis (or equivalent on urine protein-to-creatinine ratio or urine albumin-to-creatinine ratio)\n* Preoperative anemia (hemoglobin \\\u003C11g\u002Fdl for men and women)\n* History of prior CABG\n* Age ≥65\n\nExclusion Criteria\n\n* Preexisting AKI within seven days before surgery as defined by KDIGO stage ≥1 (serum creatinine-based)\n* Kidney transplant status\n* Off-pump cardiac surgery\n* ESRD\n* Emergent cardiac surgery\n* Pregnancy\n* Patient enrolled in competing research studies that may affect outcomes\n* Patients held in an institution by legal or official order","ALL","18 Years",{"count":80,"type":81},304,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery",[87,88,89],"Ischemia Reperfusion Injury","Myocardial Injury","Acute Kidney Injury","2025-03-10",{"date":92,"type":93},"2025-03-12","ACTUAL",{"date":95,"type":93},"2021-09-13",{"date":97,"type":81},"2025-06-30",{"name":5,"class":6},1]